Rex MD AI Market Strategy Report - ED Treatment Pills

Answer Capsule

Rex MD shows the sharpest decline among mid-tier brands in the ED treatment pills AI recommendation benchmark, with valid recommendation coverage falling 8.5 percentage points from July 2026 to September 2026. The brand is being named less often, not just recommended less, with mention presence dropping from 21.2% to 13.8% over the same period. Rex MD registered its first rank-one recommendations in September 2026, though from a very small base. The clearest weakness is visibility loss earlier in the AI answer-generation process, and the clearest opportunity is rebuilding presence across high-intent discovery prompts where competitors now appear in its place.

Who This Report Is For

This report is for brand, growth, and digital strategy leaders at Rex MD responsible for understanding how AI-generated recommendations are shaping provider selection in the ED treatment category.

Report Card

Executive Summary

Rex MD holds a 13.8% presence rate in September 2026, meaning the brand appears in fewer than one in seven qualified AI observations across the ED treatment pills category. Its valid recommendation coverage of 6.6% is less than half its July 2026 level of 15.1%, a decline of 8.5 percentage points classified as beyond normal variation for the series. The brand recorded 42 mentions in September 2026, down from 69 in July 2026, with 26 positive mentions, 16 neutral mentions, and no negative mentions.

The strongest cluster for Rex MD is brand recommendation discovery, which is the only cluster with qualified observations in the current public series. The weakest signal is the brand's overall presence, which dropped 7.4 percentage points from July to September, indicating Rex MD is being filtered out earlier in the AI answer-generation process rather than simply ranked lower when mentioned.

The strongest platform signal for Rex MD is Google AI Mode, where the brand recorded its first rank-one recommendations at a 2.2% rate. The clearest platform gap is Perplexity, where Rex MD has no presence at all in the September 2026 qualified set. The evidence suggests Rex MD's challenge is not placement quality when recommended, but rather being present in AI answers often enough to compete.

What Rex MD Is Winning

Rex MD's wins are narrow but measurable. The brand recorded its first rank-one recommendations in September 2026, moving from 0.0% in July to 1.0%, with three rank-one observations. This is a small base, but it signals that Rex MD can still capture the top recommendation slot in specific prompt contexts.

The brand also maintains a clean sentiment profile with no negative mentions in the September 2026 set. Its net sentiment score of 0.619 is lower than most competitors, but the absence of negative framing means the brand is not being actively cautioned against in AI responses.

Rex MD's average recommended rank of 2.56 when it does receive rank-eligible recommendations indicates that when the brand appears in a recommendation list, it tends to appear near the top rather than buried in lower positions.

Where Rex MD Has the Clearest AI Visibility Gaps

Questions This Section Answers

• What is the most significant gap in Rex MD's AI presence?
• How does Rex MD's zero presence on Perplexity compare with competitors?
• What does the decline in valid recommendation count mean for interpreting the data?

Rex MD's most significant gap is raw presence. The brand appears in only 13.8% of qualified observations, down from 21.2% in July 2026. This is not a placement problem; it is a visibility problem. Rex MD is being named less often across AI surfaces, which means it is being excluded from consideration before recommendation lists are even formed.

The Perplexity gap is stark. Rex MD has zero presence on Perplexity in the September 2026 qualified set, while competitors like Ro appear in 61.1% of Perplexity observations and Hims appears in 66.7%. This platform absence removes Rex MD from an entire surface family where buyers may be conducting discovery research.

Rex MD's valid recommendation count fell from 49 in July 2026 to 20 in September 2026, a drop of 29 recommendations. The small count caveat is important here; with only 20 valid recommendations in September, individual placements carry outsized weight. The core issue is that Rex MD is being displaced earlier in the answer-generation process, likely by brands with stronger source footprints and more consistent citation support across high-intent prompt clusters.

Biggest Opportunity

Questions This Section Answers

• What is Rex MD's clearest path to rebuilding AI recommendation coverage?
• Why does mention presence matter more than placement quality for Rex MD?

Rex MD's clearest opportunity is rebuilding mention presence across the brand recommendation discovery cluster. The brand's placement quality when recommended is reasonable, with an average recommended rank of 2.56, but it is not being included in enough answers to convert that placement quality into meaningful coverage. The path forward is to identify which prompt categories drove the July-to-August loss in mention presence and which brands are appearing in Rex MD's place, then target the public evidence layer that supports those competing recommendations.

Competitive Landscape

Questions This Section Answers

• Where does Rex MD stand relative to the category leaders in the September 2026 benchmark?
• Which competitors hold the strongest recommendation-stage positions in this category?

Hims and Ro hold dominant recommendation-stage strength in the ED treatment pills category, with GoodRx Care emerging as a strong third player. Rex MD sits in the lower tier with a 6.6% valid recommendation coverage rate, behind mid-tier brands like Lemonaid Health and PlushCare.

Average recommended rank covers rank-eligible recommendations only.

Rex MD's top-three rate of 4.59% and rank-one rate of 0.98% place it well behind the category leaders. The brand's average recommended rank of 2.56 is competitive with stronger brands, but the low frequency of rank-eligible recommendations means that placement quality rarely translates into visible buyer shortlist inclusion.

Prompt Evidence

Google AI Mode / Brand Recommendation Prompt: "best online pharmacy" Result: Rex MD appeared in a small share of responses with its first rank-one recommendation in this surface.

ChatGPT / Brand Recommendation Prompt: "ed meds online" Result: Rex MD was present in 27.3% of ChatGPT observations with a 27.3% valid recommendation coverage, its strongest platform performance.

Perplexity / Brand Recommendation Prompt: "generic viagra" Result: Rex MD had no presence in Perplexity observations, indicating exclusion from this surface family entirely.

What CiteWorks Studio Would Do Next

Phase 1: AI Market Discovery Audit Map which high-intent prompts Rex MD is winning, losing, and absent from across all six AI surface families.

Phase 2: Recommendation Readiness Plan Identify the specific prompt categories where Rex MD lost mention presence between July and September and prioritize recovery targets.

Phase 3: Owned Answer Layer Buildout Develop owned content that answers the discovery and evaluation questions where Rex MD needs to regain visibility.

Phase 4: Citation / Authority Layer Development Build the public evidence layer that supports Rex MD's inclusion in AI-generated recommendation lists, with emphasis on Perplexity where the brand is currently absent.

Phase 5: Monthly AI Visibility and Recommendation Tracking Track presence rate, valid recommendation coverage, and placement metrics monthly to measure recovery against the July 2026 baseline.

Why This Matters

Questions This Section Answers

• How are AI-generated recommendations affecting which ED treatment providers reach buyer shortlists?
• What is the consequence of declining presence for Rex MD against competing brands?

AI-generated recommendations are increasingly shaping which ED treatment providers appear on buyer shortlists. Rex MD's declining presence means the brand is being excluded from consideration before buyers even see a recommendation list, and competitors are capturing the discovery prompts where Rex MD previously appeared.

Presence alone is not enough, but without presence, recommendation coverage is impossible. The next move for Rex MD is targeted correction of the prompt, page, and citation layers that determine whether the brand is included in AI answers at all.

Core Metrics

Sentiment Score

Sentiment Score = (positive mentions × 1 + neutral mentions × 0 + negative mentions × -1) / total mentions

For Rex MD in September 2026, this equals (26 × 1 + 16 × 0 + 0 × -1) / 42, producing a score of 0.619.

This matters because unclassified mention counts are misleading. Share of voice is a diagnostic metric, not a business KPI. A positive recommendation, neutral reference, cautionary mention, and competitor-displaced mention are not equal. Counting all mentions as wins is bad measurement. Classified sentiment is required before interpreting AI visibility, because a brand can be widely mentioned yet rarely recommended, or recommended often with mixed framing.

Sentiment by Platform

Methodology

1. This report is a benchmark-based analysis of Rex MD's AI visibility and recommendation performance in the ED treatment pills category, based on the LLM Authority Index AI Market Discovery Index public benchmark and CiteWorks Studio interpretation of that data.
2. The reporting window is September 2026, with trend comparisons to July 2026 and August 2026 where the public series supports them.
3. Six canonical AI/search surface families were tracked: ChatGPT, Copilot, Gemini, Perplexity, AI Overviews, and AI Mode.
4. The September 2026 benchmark is built from 305 qualified observations, derived from 800 raw prompt-surface observations after excluding irrelevant, off-topic, and reserved prompts.
5. The competitor universe includes 10 tracked brands: Hims, Ro, GoodRx Care, Lemonaid Health, PlushCare, BlueChew, Blink Health, Rex MD, K Health, and Optum.
6. All qualified observations in the current public series fall into the brand recommendation buyer-intent class. The public benchmark does not yet contain qualified observations for pricing and value or multi-brand comparison prompts.
7. Stage 0 extraction captured prompt-level observations including query, AI surface, answer, brand outcome, recommendation placement, sentiment, and citations where exposed.
8. A mention is defined as any appearance of a brand in a qualified observation, regardless of whether the brand is recommended.
9. A valid recommendation is defined as an observation where the brand appears in a recommendation context, distinct from a neutral reference or comparison-anchor mention.
10. Limitations: The public benchmark does not measure market share, sales, or revenue attribution from AI recommendations. It does not capture every possible AI response a user might receive. Movement between months identifies changes worth investigating but does not by itself establish the cause of those changes. Rex MD's small valid recommendation count of 20 in September means individual placements carry outsized weight, and percentage movements should be interpreted with this limited base in mind.

Get Your AI Visibility Audit

The public benchmark shows where Rex MD is winning and losing, but a company-level audit is needed to reveal which high-intent prompts the brand is losing, which competitors are capturing those recommendations, and what evidence layer would move the outcome. A company-specific AI visibility audit maps those prompt, surface, competitor, ranking, sentiment, and evidence-source patterns into a prioritized visibility strategy.